影像组学推断的免疫程序映射胶质母细胞瘤的治疗背景
本研究基于多区域MRI影像组学构建非侵入性放射基因组框架,关联胶质母细胞瘤免疫微环境状态与机制性治疗假设。内部队列223例(训练156例/验证67例),外部TCGA-GBM队列98例。影像组学模型在训练、验证和外部队列的C-index分别为0.787、0.701和0.702。转录组分析定义热、温、冷免疫状态(12例13.6%、23例26.1%、53例60.2%),并据此提出假设性治疗分配。
要点
- 影像组学模型可无创预测胶质母细胞瘤总生存,外部验证C-index为0.702。
- 影像组学联合临床模型外部测试C-index 0.730,优于临床模型0.639。
- 基于T细胞标志物和IFN-γ反应聚类定义热/温/冷免疫状态,冷肿瘤占60.2%。
关键影像表现/征象
- 影像组学模型在训练、验证和外部队列的C-index分别为0.787(95%CI 0.741-0.826)、0.701(95%CI 0.612-0.777)和0.702(95%CI 0.638-0.760)。
- 对应时间依赖AUC均值分别为0.857、0.773和0.805。
- 集成预后评分在所有队列中均与总生存独立相关。
- 外部测试中影像组学联合临床模型C-index为0.730,高于临床模型0.639。
- 转录组分析显示肿瘤微环境组成异质性和区室限制性免疫程序。
诊断标准与关键数值
- 免疫状态由T细胞标志物直接表达和干扰素-γ反应ssGSEA评分经K-means聚类定义。
- 最终分类为热12例(13.6%)、温23例(26.1%)、冷53例(60.2%),bootstrap稳定性调整Rand指数0.86。
- 影像组学模型预测总生存的C-index:训练0.787(95%CI 0.741-0.826)、验证0.701(95%CI 0.612-0.777)、外部0.702(95%CI 0.638-0.760)。
临床应用与阅片要点
- 影像组学评分可作为胶质母细胞瘤术前无创预后分层工具,辅助识别高风险患者。
- 联合临床模型可提升预后预测性能,但需独立验证后方可用于临床决策。
- 免疫状态分类及治疗分配为探索性假设,不应直接指导治疗选择。
局限性
- 免疫状态分类和治疗分配为探索性、假设生成性,未分配疗效评分。
- 需独立放射基因组验证和前瞻性验证后方可临床应用。
- 研究为回顾性设计,外部验证队列样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: To develop and evaluate a noninvasive radiogenomic framework linking multiregional magnetic resonance imaging radiomics to glioblastoma immune microenvironment states and mechanism-based therapeutic hypotheses.
MATERIALS AND METHODS: The internal University of California San Francisco-Preoperative Diffuse Glioma MRI dataset (UCSF-PDGM) cohort included 223 patients, divided into training (n = 156) and validation (n = 67) sets; 98 The Cancer Genome Atlas glioblastoma dataset (TCGA-GBM) patients formed an independent external cohort. A block/atom-based ensemble radiomics model was developed for overall survival prediction. Matched bulk RNA sequencing from 88 external-cohort patients underwent non-negative least-squares deconvolution using a GSE84465-derived single-cell reference, pathway analysis, and single-cell-supported interpretation. Exploratory Hot, Warm, and Cold states were defined by K-means clustering of direct T-cell-marker expression and interferon-gamma-response single-sample gene set enrichment analysis scores. Therapeutic candidates were organized by immune state and mechanism without assigning efficacy scores.
RESULTS: The radiomics model achieved C-indices of 0.787 (95% confidence interval [CI], 0.741-0.826), 0.701 (95% CI, 0.612-0.777), and 0.702 (95% CI, 0.638-0.760) in the training, validation, and external cohorts, respectively; corresponding mean time-dependent areas under the curve were 0.857, 0.773, and 0.805. The ensemble prognostic score remained independently associated with overall survival in all cohorts. In external testing, the radiomics-plus-clinical model showed a higher C-index than the clinical-only model (0.730 vs 0.639). Transcriptomic analyses indicated heterogeneous tumor-microenvironment composition and compartment-restricted immune programs. The final classification comprised 12 Hot (13.6%), 23 Warm (26.1%), and 53 Cold (60.2%) tumors and showed bootstrap stability (adjusted Rand index, 0.86). Immune-state-specific therapeutic assignments were interpreted as hypothesis-generating.
CONCLUSIONS: This framework links magnetic resonance imaging-derived prognostic phenotypes to exploratory immune states and mechanism-based therapeutic hypotheses in glioblastoma. Independent radiogenomic and prospective validation is required before clinical application.
引用
- Kawahara D, Kishi M, Kadooka Y, et al. Radiomics-Inferred Immune Programs Map Therapeutic Contexts in Glioblastoma. Acad Radiol. 2026. PMID: 42686490. doi:10.1016/j.acra.2026.08.057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。